

Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer — Video Program

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III TAILORx trial demonstrated which of the following results with regard to the primary (invasive disease-free survival) and secondary (distant relapse-free interval) endpoints for patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer and a Recurrence Score® of 11 to 25?**

 - Inferiority of chemoendocrine therapy to endocrine therapy alone
 - Noninferiority of chemoendocrine therapy to endocrine therapy alone
 - Superiority of chemoendocrine therapy to endocrine therapy alone
- 2. The Phase III MONALEESA-7 trial demonstrated a significant improvement in overall survival with the addition of ribociclib to endocrine therapy for which subgroup of patients with HR-positive, HER2-negative advanced breast cancer?**

 - Only premenopausal patients
 - Only postmenopausal patients
 - Pre-, peri- and postmenopausal patients
- 3. The SOLAR-1 trial comparing the PI3-kinase inhibitor alpelisib with fulvestrant to fulvestrant alone demonstrated a significant improvement in progression-free survival (PFS) with alpelisib for patients with HR-positive, HER2-negative advanced breast cancer with which PIK3CA mutation status?**

 - PIK3CA mutation
 - No PIK3CA mutation
 - Both a and b
- 4. Which of the following statements is true regarding PFS results from the SOLAR-1 trial of alpelisib for HR-positive, HER2-negative advanced breast cancer?**

 - Alpelisib is not effective in patients who have previously received a CDK4/6 inhibitor
 - Alpelisib is effective only in patients who have previously received a CDK4/6 inhibitor
 - PFS benefit with alpelisib was similar among patients with and without prior exposure to a CDK4/6 inhibitor
- 5. The Phase II monarchHER trial evaluating trastuzumab and abemaciclib with or without fulvestrant versus trastuzumab with standard chemotherapy for women with HR-positive, HER2-positive advanced breast cancer demonstrated which of the following PFS results?**

 - PFS was significantly improved with the combination of trastuzumab and abemaciclib compared to trastuzumab and chemotherapy
 - PFS was significantly improved with the combination of abemaciclib, fulvestrant and trastuzumab compared to trastuzumab and chemotherapy